Heron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Update

Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totalling 29,980,000 shares, a growth of 8.9% from the November 30th total of 27,540,000 shares. Based on an average daily volume of 3,110,000 shares, the days-to-cover ratio is currently 9.6 days.

Institutional Investors Weigh In On Heron Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Clearline Capital LP boosted its stake in Heron Therapeutics by 48.9% in the third quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company's stock valued at $4,431,000 after acquiring an additional 731,246 shares in the last quarter. Congress Park Capital LLC boosted its position in shares of Heron Therapeutics by 25.3% in the 3rd quarter. Congress Park Capital LLC now owns 1,978,078 shares of the biotechnology company's stock valued at $3,936,000 after purchasing an additional 399,577 shares during the period. Marshall Wace LLP grew its stake in Heron Therapeutics by 256.2% during the 2nd quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company's stock worth $6,164,000 after buying an additional 1,266,697 shares during the last quarter. AQR Capital Management LLC increased its position in Heron Therapeutics by 1,460.9% during the second quarter. AQR Capital Management LLC now owns 607,135 shares of the biotechnology company's stock worth $2,125,000 after buying an additional 568,238 shares during the period. Finally, GSA Capital Partners LLP lifted its stake in Heron Therapeutics by 18.4% in the third quarter. GSA Capital Partners LLP now owns 512,736 shares of the biotechnology company's stock valued at $1,020,000 after buying an additional 79,680 shares during the last quarter. Institutional investors and hedge funds own 80.01% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. StockNews.com downgraded shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday. Needham & Company LLC reaffirmed a "buy" rating and set a $4.00 price objective on shares of Heron Therapeutics in a research report on Wednesday, December 4th.

Heron Therapeutics Stock Up 1.3 %

Heron Therapeutics stock traded up $0.02 during trading on Wednesday, reaching $1.53. The stock had a trading volume of 1,685,491 shares, compared to its average volume of 2,683,605. Heron Therapeutics has a 52-week low of $1.04 and a 52-week high of $3.93. The stock has a market cap of $232.71 million, a PE ratio of -8.50 and a beta of 1.67. The business has a 50 day moving average price of $1.52 and a 200 day moving average price of $2.09.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, hitting analysts' consensus estimates of ($0.03). The firm had revenue of $32.81 million for the quarter, compared to analyst estimates of $36.40 million. During the same quarter in the previous year, the firm posted ($0.17) EPS. On average, equities analysts predict that Heron Therapeutics will post -0.13 EPS for the current fiscal year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.